Life after first-line chemotherapy in malignant pleural mesothelioma: A north-east england Experience

Clinical Oncology

Volumn 22, Issue 3, 2010, Pages 231-235

  Steer, J ^a   Bough, G ^b   Razak, A R A ^b,c   Meachery, G J ^a   Hughes, A ^b  

^a SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chemotherapy; Mesothelioma; Palliative; Pemetrexed; Radiotherapy; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; MITOMYCIN; NAVELBINE; PEMETREXED; PLATINUM; VINBLASTINE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; CANCER CONTROL; CANCER GROWTH; CANCER RELAPSE; CERVICAL LYMPH NODE; CONTROLLED STUDY; DIPLOPIA; DRUG RECHALLENGE; DYSPHONIA; DYSPNEA; FEMALE; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RETREATMENT; SYMPTOMATOLOGY; SYSTEMIC THERAPY; THORAX PAIN; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ENGLAND; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLEURAL NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77950182035     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.01.009     Document Type: Article

References (10)

1. Wagner J.C., Sleggs C.A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960, 17:260-271.
2. Bianchi C., Giarelli L., Grandi G., Brollo A., Ramani L., Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997, 6:162-166.
3. Kindler H.L. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008, 9:171-179.
4. van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23:6881-6889.
5. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
6. Jassem J., Ramlau R., Santoro A., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26:1698-1704.
7. Manegold C., Symanowski J., Gatzemeier U., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005, 16:923-927.
8. Razak A.R., Chatten K.J., Hughes A.N. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer 2008, 60:294-297.
9. Hughes A., Calvert P., Azzabi A., et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002, 20:3533-3544.
10. O'Rourke N., Garcia J.C., Paul J., Lawless C., McMenemin R., Hill J. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007, 84:18-22.